Table 2.

Clinical Outcomes of Pharyngeal and Rectal Infections Treated With 360 mg Intramuscular Gentamicin, Gentamicin Minimum Inhibitory Concentration (MIC), Peak Serum Concentration (C_max), Weight-Based Dosing, and C_max/MIC Ratio

Study ID	Pharyngeal Treatment Outcome	Rectal Treatment Outcome	Gentamicin MIC, µg/mL	Cmax, µg/mL	Weight-based Dosing, mg/kg	Cmax/MIC Ratio
1	Failure	NA	8	20.7	5.12	2.59
2	Failure	NA	8	24.7	4.36	3.09
3	Failure	Cure	8a	>30	6.73	>3.75
4	Unevaluable	NA	NA	>30	4.9	NA
5	Cure	NA	8	20.9	3.97	2.61
6	Failure	NA	8	16.3	3.89	2.04
7	Cure	NA	8	16.8	4.56	2.1
8	Failure	NA	4	28.2	6.84	7.05
9	Failure	NA	8	Missing	3.64b	NA
10	Unevaluable	Cure	4c	15	4.59	3.75c
11	Failure	NA	4	15	3.75b	3.75
12	Unevaluable	NA	NA	15.7	4.22b	NA
13	Failure	NA	8	Missing	4.07	NA

Abbreviations: C_max, peak serum concentration; ID, identifier; MIC, minimum inhibitory concentration; NA, not applicable.

^aPharyngeal and rectal isolate with same gentamicin MIC.

^bAdjusted body weight used to determined weight-based dosing for obese participants (body mass index >30 kg/m²).

^cMIC and C_max/MIC ratio are reported for rectal isolate.